Welcome to our dedicated page for Promis Neuroscie news (Ticker: PMN), a resource for investors and traders seeking the latest updates and insights on Promis Neuroscie stock.
ProMIS Neurosciences Inc. reports clinical-stage biotechnology developments around antibody therapeutics and vaccines that target toxic misfolded proteins in neurodegenerative diseases. Company news centers on PMN310, its lead humanized monoclonal antibody for Alzheimer’s disease, the PRECISE-AD clinical program, FDA Fast Track designation, biomarker research involving plasma pTau, and scientific publications or conference presentations tied to Alzheimer’s disease, ALS, and Parkinson’s disease.
Updates also cover operating and financial results, governance matters, shareholder votes, capital-structure actions, and investor conference participation. The company’s research disclosures emphasize its proprietary discovery platform and selective targeting of disease-specific toxic protein species rather than broader amyloid plaque binding.
ProMIS Neurosciences Inc. (Nasdaq: PMN) has closed a fully subscribed private placement of 1,383,755 Units at US$5.40 each, raising gross proceeds of US$7,472,277. Each Unit consists of a Common Share and a quarter Warrant, with each full Warrant exercisable at US$7.50 for five years. Proceeds will fund the first-in-human study of lead candidate PMN310 in 2023, pending FDA approval, while also supporting IP expansion and working capital. ProMIS focuses on developing antibody therapeutics for neurodegenerative diseases like Alzheimer’s, ALS, and MSA.
ProMIS Neurosciences (Nasdaq: PMN) has appointed Gail M. Farfel, Ph.D., as its new Chief Executive Officer, effective September 19, 2022. With over 25 years of experience in neurology drug development, Dr. Farfel aims to lead ProMIS towards becoming a clinical-stage biotechnology company with multiple product opportunities. The company achieved significant milestones in the past 18 months, including a successful Nasdaq listing and the IND submission for their lead Alzheimer’s drug, PMN310, expected by year-end.